This project was submitted in the following language: English (en).

Projektbeschreibung

A novel implantable hemodynamic monitor in heart failure

Cor/log 1P2O is a novel implantable system for fast and reliable hemodynamic monitoring of both body and heart muscle oxygenation plus systemic venous pressure to detect heart failure. Wireless continuous connection to a trusted cloud allows fast doctor reaction and efficient corrective drug management.

Cor/log 1P2O system consists of two product types:
- Cor/log Probe 1P2O, semi-implant for inpatient use
- Cor/log Implant 1P2O, full implant for outpatient remote mobile monitoring

Land, Region

Deutschland [BAYERN]

Beginn

August 2017

Veranschlagte Projektkosten

EUR 2 Mio.

Sektor 

Forschung, Entwicklung und Innovation

Gesundheit

Eigentum an Vermögenswerten

Privat

Art des Projekts

Grüne Wiese

Projektstatus

Bau begonnen

Art der Einnahmen

Marktgestützt

Erwartete neue Arbeitsplätze

20

Ökonomisches Kalkül / Geschäftsmodell

Our targeted disease is heart failure (HF), a major global public health problem with a worldwide
prevalence of 38 million patients, which leads to 1.8 million deaths in Europe every year. In Germany alone 1.6 million people suffer from HF. HF patients need to frequently revisit hospitals, and this induces high costs while negatively impacting the quality of life.

In the US, heart failure costs the US$31 billion a year with 80% of those costs spent on hospital treatment. HF patients stay on average 5 to 10 days in hospital and around 45% of them need to revisit hospital within the following 60 days.

It is estimated that HF patients cost around 3,000 to 4,000 €/patient/year in Germany, and around 15,000 US$/patient/year in the US. The average survival time for patients diagnosed of HF is 7 years.

Einzelheiten der Finanzierung

Projektfinanzierung gesichert: EUR 0.100 Mio. (5 %)

Finanzierungsquelle: Privat

MI Medical Innovation is currently seeking €2M with majority silent share by value to complete product development, clinical investigation and regulatory compliance in EU, file additional IP, and launch its first product in the European market.

Der Projektträger hat eine Finanzierung durch die EU oder die EIB beantragt oder beabsichtigt, dies zu tun

Zusatzinformationen zum Projekt

Market Opportunity:
We will focus initially on diabetic patients who also suffer from heart failure complication to whom, implantation of our device, during up to six months, provides better drug regimen adjustment and prevents repeated stays in hospitals.

Regulatory compliance:
Cor/log Probe 1P2O complies to EU MDD 93/42/EEC in transition to EU-MDR, while Cor/log Implant 1P2O complies to EU-MDR

Exit Strategy:
Following successful product launch and achieving revenue milestones, the company will explore
acquisition opportunities.

Veröffentlichung: 18/10/2017 | Zuletzt aktualisiert am: 18/10/2017

Die Kommission erklärt weder ausdrücklich noch stillschweigend, dass die Projektinformationen fehlerfrei sind, und übernimmt hierfür keine Gewähr. Die Bereitstellung der Projektinformationen erfolgt ohne jegliche Garantie, Bedingung oder Gewährleistung bezüglich ihrer Richtigkeit.